Feed aggregator

CSL Behring Bolsters Gene Therapy Pipeline with uniQure's Hemophilia B Treatment

Biospace news - Thu, 06/25/2020 - 02:00
CSL Behring bolstered its growing gene therapy portfolio with the acquisition of global rights to uniQure’s gene therapy program for hemophilia B that has a price tag of up to $2 billion.

Novartis, Current and Former Units Agree to Pay More than $346 Million to Settle U.S. Bribery Cha...

Biospace news - Thu, 06/25/2020 - 02:00
Novartis, Novartis Hellas and Alcon Inc. have agreed to pay a total of more than $346 million to settle bribery charges under the Foreign Corrupt Practices Act (FCPA), which is a U.S. anti-bribery law.

In Reorganization, Sangamo Splits R&D Unit into Separate Entities

Biospace news - Thu, 06/25/2020 - 02:00
The Brisbane, California-based company announced its plans to separate the two units and treat them as individual operations with individual managers.

Protein Motion Company Relay Therapeutics Files for $200 Million IPO

Biospace news - Thu, 06/25/2020 - 02:00
Relay Therapeutics was the No. 3 company in BioSpace’s NextGen Bio Class of 2018, Top 20 Life Science Startups to Watch in 2018.

Sosei Heptares and AbbVie Partner on Inflammatory and Autoimmune Diseases

Biospace news - Thu, 06/25/2020 - 02:00
The companies will work to discover, develop and commercialize novel therapies that modulate G protein-coupled receptor (GPCR) targets that AbbVie selects.

BioSpace Global Roundup, June 25

Biospace news - Thu, 06/25/2020 - 02:00
Biopharma and life sciences companies provide updates on their pipelines and business plans.

Sanofi Considering Additional Restructuring and Up to 1,000 Job Cuts

Biospace news - Thu, 06/25/2020 - 02:00
According to a brief report by Reuters, the drug company plans to hold meetings with staff representatives tomorrow and Monday of next week to describe a restructuring plan, according to four sources familiar with the matter.

Enterome Raises $52.6 Million to Advance Cancer Immunotherapies and OncoMimics Platform

Biospace news - Thu, 06/25/2020 - 02:00
Enterome SA, based in Paris and Cambridge, Massachusetts, announced a new financing totaling $52.6 million (€46.3 million). This was a Series E round.

Regenerative Medicine Needs a New, Digital Supply Chain

Biospace news - Thu, 06/25/2020 - 02:00
The supply chain that exists for traditional pharmaceuticals is woefully insufficient for regenerative medicine, according to Robert Lechich, principal manufacturing and supply chain consultant for Global OT/IT – Quality Services.

U.S. Government Alleges Regeneron Used Kickbacks to Boost Eylea Sales

Biospace news - Thu, 06/25/2020 - 02:00
Regeneron Pharmaceuticals said it will vigorously defend federal charges that it was involved in a kickback scheme to bolster sales of its blockbuster macular degeneration drug, Eylea.

The Question You Should Always Ask at the End of an Interview

Biospace news - Thu, 06/25/2020 - 02:00
Don’t forget that you’re also interviewing the company, the team and the manager that you’d be working for, should you be offered the position and accept.

Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges

World Pharma News - Wed, 06/24/2020 - 12:00
Novartis revealed the healthcare and pharma industry has emerged as a desired career destination for tech talent during the COVID-19 pandemic, in the Powerful Pairing research report launched today.

The research - which covered 2,502 tech professionals in the US, UK, Germany, China and India, conducted between May and June 2020 - targeted respondents from a variety of sectors and organizations with the objective to study perception shifts of the industry in the wake of the global COVID-19 pandemic.

FDA announces first of its kind pilot program to communicate patient reported outcomes from cancer clinical trials

World Pharma News - Wed, 06/24/2020 - 10:00
The U.S. Food and Drug Administration launched Project Patient Voice, an initiative of the FDA’s Oncology Center of Excellence (OCE). Through a new website, Project Patient Voice creates a consistent source of publicly available information describing patient-reported symptoms from cancer trials for marketed treatments.

Yumanity and Merck Ink $500 Million+ Deal for Neurodegenerative Diseases

Biospace news - Wed, 06/24/2020 - 02:00
Yumanity Therapeutics and Merck signed a strategic research and license deal for two Yumanity programs.

Fauci, Other Top Healthcare Officials Outline Necessary Strategies to Combat COVID-19

Biospace news - Wed, 06/24/2020 - 02:00
Speaking before Congress on Tuesday, Dr. Anthony Fauci urged people to adopt strategies that involve wearing a mask in public, maintaining social distance and avoiding large gatherings of people.

AsclepiX Launches with $35 Million to Study Diseases of the Eye and Cancer

Biospace news - Wed, 06/24/2020 - 02:00
Baltimore-based AsclepiX Therapeutics closed a $35 million Series A financing.

BIO to Outline Key Priorities for Next Pandemic During Senate Hearing

Biospace news - Wed, 06/24/2020 - 02:00
COVID-19-related testimonies will continue in Congress today, with representatives from the Biotechnology Innovation Organization (BIO) expected to address the current pandemic as well as key priorities that will need to be in place in order to effectively respond to the next global viral threat.

Biopharma Update on the Novel Coronavirus: June 24

Biospace news - Wed, 06/24/2020 - 02:00
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 24, 2020.

New Data Shows 718 Pipeline Drugs Now Associated with COVID-19

Biospace news - Wed, 06/24/2020 - 02:00
New information released Tuesday by GlobalData showed that there are now more than 718 pipeline drugs associated with COVID-19. In addition, 70% of these products are in the discovery or preclinical stages.

FDA Approves Phase III Study of Fulcrum's Losmapimod in COVID-19

Biospace news - Wed, 06/24/2020 - 02:00
Shares of Fulcrum Therapeutics were up more than 14% in premarket trading after the company announced it will begin the Phase LOSVID III study to assess losmapimod as a potential treatment of COVID-19.